Study to Evaluate Broadlumab vs Placebo and Ustekinumab

Part of paid clinical trials in San Diego, California.

Sponsor
MedDerm Associates
Study ID
NCT02786732
Phase
PHASE3
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Accepted

Interventions

  • 210mg Brodalumab — BIOLOGICAL
    Brodalumab 210mg administered subcutaneously
  • 140mg Brodalumab — BIOLOGICAL
    Brodalumab 140mg administered subcutaneously
  • Ustekinumab — BIOLOGICAL
    Ustekinumab 45mg or 90mg adminstered subcutaneously
  • Placebo — BIOLOGICAL
    Placebo administered subcutaneously

Study Details

The purpose of the study is to evaluate the efficacy and safety of Induction and Maintenance Regimens of Brodalumab compared with Placebo and Ustekinumab in subjects with moderate to severe plaque psoriasis.

Key Dates

Start date
Aug 31, 2012
Status verified
May 2016
Primary completion
Jun 30, 2017
Completion
Oct 31, 2017

Study Design

Enrollment
15 participants (actual)
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: 210mg Brodalumab
    Administered by subcutaneous injection until Week 12
  • Experimental: 140mg Brodalumab
    Administered subcutaneous injection until Week 12
  • Active Comparator: Ustekinumab
    Administered subcutaneous injection until Week 52
  • Placebo Comparator: Placebo
    Administered subcutaneous injection until Week 12

Primary Outcome Measure

PASI Improvement [ Time Frame: 12 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
MedDerm AssociatesSan DiegoCalifornia92103-

Find similar trials in San Diego, CA

By condition
Psoriasis
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
MedDerm Associates· San Diego, CA

Related Studies